Cipla, leading drug maker, announced that it has been awarded USD 188.95 million of Global Fund ARV Tender. Cipla has been selected as a 'Panel Supplier' for a supplier partnership agreement.

The contract is effective from the Jan. 1, 2015 and will run for a period of three years. The supplies will begin from Q4 FY2015.

Subhanu Saxena, MD & Global CEO, Cipla, said, ''We are extremely proud to have won this tender from Global Fund. Cipla has been committed to the cause of HIV/AIDS for over two decades and this tender offers us a great opportunity to make HI V/AIDS treatment accessible to more than 140 countries through Global Fund.

Cipla has a long-term association with Global Fund since 2002. Last year, Cipl a has been one of the suppliers who has been awarded with a long-term  contract for supplying an ti-malarial drugs.

The anti-retrovirals drugs will be manufactured in Cipla's state -of-the-art manufacturing facilities in India, which has been approved by various international regulatory agencies.

Shares of the company gained Rs 1.7, or 0.26%, to trade at Rs 663.70. The total volume of shares traded was 472,069 at the BSE (10.59 a.m., Friday).